Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

BPC-157 vs KPV

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

BPC-157: CKPV: D
AttributeBPC-157KPV
CategoryHealing & RecoveryAnti-Inflammatory / Immune
Evidence RatingC — Phase I–II Clinical TrialsD — Preclinical
Clinical StatusResearch-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.Preclinical. No formal clinical trials completed. Used in compounding pharmacy protocols. Removed from FDA Category 2 on April 15, 2026.
MechanismBPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors...KPV exerts anti-inflammatory effects through a mechanism distinct from the parent α-MSH hormone. Rather than acting through melanocortin receptors (which would trigger pigmentation), KPV is transported into cells via PepT1, a di/tripeptide transporter expressed on intestinal epithelial cells and imm...
Half-Life~15 min IV (animal data); oral activity persists 24+ hours~2 hours (SC); shorter oral due to GI degradation
BioavailabilityIM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation—
Molecular Weight~1419.5 g/mol~342.4 g/mol
WADA StatusProhibitedNot Listed
Research Half-Life~15 min IV (animal data); oral activity persists 24+ hours~2 hours (SC); shorter oral due to GI degradation
Key Use Cases
  • Injury Recovery
  • Gut Health
  • Gut Health
  • Immune Support
Safety Concerns
  • No completed randomized controlled human clinical trials for safety assessment
  • Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology
  • FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
  • No significant adverse effects reported in preclinical studies
  • Does not cause skin darkening (unlike Melanotan peptides)
  • No formal human safety trials have been conducted
Contraindications
  • Pregnancy and breastfeeding (no safety data)
  • Active cancer or history of cancer (theoretical concern due to potent angiogenesis promotion; mechanistic overlap with tumor vascularization)
  • Individuals on anticoagulants (BPC-157 affects clotting and vessel constriction resolution)
  • Autoimmune conditions (immunogenicity risk noted by FDA)
  • Pregnancy and breastfeeding (no safety data)
  • Known hypersensitivity to α-MSH-derived peptides
  • Immunosuppressed patients (theoretical — anti-inflammatory mechanism)
Regulatory (US)Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned.Not FDA-approved. Removed from FDA Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026. Research chemical.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationBPC-157KPV
Purity Standard≥98%≥98%
CAS Number137525-51-067727-97-3
Molecular FormulaC₆₂H₉₈N₁₆O₂₂C₁₆H₃₀N₄O₄
Available Formats5mg, 10mg, 10mg10mg
Batch COAs Published3 on file1 on file
Stock StatusIn stockIn stock

Availability at Volta Peptides

BPC-157 5mg

≥98% purity · HPLC verified · In stock

$34

KPV 10mg

≥98% purity · HPLC verified · In stock

$34

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.